ClinicalTrials.Veeva

Menu

Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region (COCO_Vi_LATE)

T

Tourcoing Hospital

Status

Unknown

Conditions

Covid19

Treatments

Other: Questionnaire
Other: medical consultation

Study type

Observational

Funder types

Other

Identifiers

NCT04817293
RIPH_2021_01

Details and patient eligibility

About

Several publications document the occurrence of prolonged or late-onset symptoms beyond 3 weeks after the first clinical manifestations of SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory events or other mechanisms that are not yet well understood. The psychosomatic origin secondary to psychiatric disorders prior to the infection or in reaction to it is also to be evoked. The identification of the clinical manifestations observed, and their clinical and paraclinical evolution are essential to better understand the natural evolution of COVID-19, to specify the physiopathological mechanisms and to identify potential avenues of management for the patients. In addition, the impact of COVID-19 infection on primary care visits is not known. In general practice, these patients benefit from explorations and even diagnoses that may explain the persistence of symptoms (autoimmune diseases, thrombosis, somatoform disorders, hyperventilation syndrome, etc.).

The objective of the COCO_Vi_LATE project is to carry out a cross-sectional study of patients presenting persistent and/or recurrent symptoms after an infection with SARS-COV-2 who will be compared to individuals with a short form of infection with COVID-19

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

A- For COVID cases:

  1. Consultation in a city doctor's office
  2. Positive SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
  3. Patient symptomatic or not

Definition of symptomatic :

  1. Anosmia
  2. OR CT scan suggestive of COVID 19
  3. OR ≥ 2 symptoms contemporaneous with virologic sampling among: asthenia, cough, dyspnea, fever, myalgias, dysgeusia, diarrhea AND not present previously at diagnosis

B-. For NON COVID cases:

  1. Consultation in a city doctor's office
  2. No known COVID+ serology
  3. No known RT- PCR SARS-CoV-2
  4. No clinical suspicion of COVID-19 infection

Exclusion criteria

  1. Minor patient
  2. Refusal to participate
  3. Patient under protection
  4. Patient requiring hospitalization for COVID-19 (excluding non-emergency hospitalization)
  5. Patient consulted for the following reason only: treatment monitoring, treatment renewal or certificate, hospital discharge

Trial design

1,000 participants in 2 patient groups

COVID-19 positive
Treatment:
Other: medical consultation
Other: Questionnaire
COVID-19 negative
Treatment:
Other: medical consultation
Other: Questionnaire

Trial contacts and locations

1

Loading...

Central trial contact

Solange TREHOUX, PhD; Olivier ROBINEAU, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems